Erasca/$ERAS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Erasca
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Ticker
$ERAS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
103
ISIN
US29479A1088
Website
Erasca Metrics
BasicAdvanced
$411M
-
-$0.59
1.13
-
Price and volume
Market cap
$411M
Beta
1.13
52-week high
$3.45
52-week low
$1.01
Average daily volume
1.4M
Financial strength
Current ratio
12.352
Quick ratio
12.056
Long term debt to equity
11.519
Total debt to equity
12.719
Management effectiveness
Return on assets (TTM)
-22.16%
Return on equity (TTM)
-45.82%
Valuation
Price to book
1.03
Price to tangible book (TTM)
1.03
Price to free cash flow (TTM)
-2.969
Growth
Earnings per share change (TTM)
-29.89%
3-year earnings per share growth (CAGR)
-27.63%
What the Analysts think about Erasca
Analyst ratings (Buy, Hold, Sell) for Erasca stock.
Erasca Financial Performance
Revenues and expenses
Erasca Earnings Performance
Company profitability
Erasca News
AllArticlesVideos
Erasca to Present at Upcoming Investor Conferences in June
GlobeNewsWire·1 day ago
Erasca Reports First Quarter 2025 Business Updates and Financial Results
GlobeNewsWire·2 weeks ago
Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Erasca stock?
Erasca (ERAS) has a market cap of $411M as of May 30, 2025.
What is the P/E ratio for Erasca stock?
The price to earnings (P/E) ratio for Erasca (ERAS) stock is 0 as of May 30, 2025.
Does Erasca stock pay dividends?
No, Erasca (ERAS) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Erasca dividend payment date?
Erasca (ERAS) stock does not pay dividends to its shareholders.
What is the beta indicator for Erasca?
Erasca (ERAS) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.